X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/16/2863289/0/en/Faron-Confirms-Plans-for-the-Coming-Months-Under-New-Leadership.html
https://www.globenewswire.com/news-release/2024/03/18/2847836/0/en/Inside-Information-Additional-Positive-Data-from-the-Phase-1-Part-of-the-BEXMAB-Study-in-Both-Higher-Risk-HMA-Failed-MDS-and-r-r-AML.html
https://www.globenewswire.com/news-release/2024/03/18/2847836/0/en/Inside-Information-Additional-Positive-Data-from-the-Phase-1-Part-of-the-BEXMAB-Study-in-Both-Higher-Risk-HMA-Failed-MDS-and-r-r-AML.html
https://www.globenewswire.com//news-release/2024/03/14/2845984/0/en/Faron-to-Host-Webcast-to-Discuss-latest-data-from-Phase-1-part-of-the-BEXMAB-Study-of-Bexmarilimab.html
https://www.globenewswire.com//news-release/2024/03/13/2845159/0/en/Faron-s-Financial-Statement-Release-January-1-to-December-31-2023.html
https://www.globenewswire.com//news-release/2024/01/25/2816292/0/en/Detailed-Analysis-of-BEXMAB-Data-Provides-Insights-into-Patient-Profiles-of-Responding-HMA-Failed-MDS-Population.html
https://www.globenewswire.com//news-release/2024/01/09/2805980/0/en/Inside-information-Faron-Announces-First-HMA-failed-MDS-Patient-Dosed-with-Bexmarilimab-as-part-of-Phase-2-of-BEXMAB-Trial.html
https://www.globenewswire.com//news-release/2024/01/03/2803031/0/en/Faron-Pharmaceuticals-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/11/2793556/0/en/Inside-information-Faron-Presents-Phase-1-Data-from-BEXMAB-in-Myeloid-Malignancies-Trial-at-the-65th-American-Society-of-Hematology-ASH-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/12/07/2792226/0/en/Faron-Announces-Publication-of-Full-Analysis-from-Phase-1-2-MATINS-Trial-of-Bexmarilimab-in-Solid-Tumors-in-Cell-Reports-Medicine.html
Market Place
Share 
